Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-γ

Maria A. Bausero, Angela Panoskaltsis-Mortari, Bruce R. Blazar, Emmanuel Katsanis

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Murine neuroblastoma, neuro-2a, was transduced with the retroviral vector MFG-granulocyte-macrophage colony-stimulating factor (GM-CSF), to examine immune stimulation conferred by localized GM-CSF production. Expression of murine GM-CSF by neuro-2a (N-2a/GM) significantly reduced its tumorigenicity. Moreover, immunization of mice with irradiated N-2a/GM cells resulted in a significant protective effect against live tumor challenge 14 days later. Approximately 41% of mice immunized with irradiated N-2a/GM versus 0% of those vaccinated with irradiated parental tumor survived. Surviving mice were rechallenged after 50 days with wild-type neuro-2a or with the Sa1 syngeneic sarcoma to discern whether the generated immunity was durable and tumor specific. All mice survived wild-type neuro-2a challenge, whereas none survived inoculation with Sa1. Because both CD4+ and CD8+ T cells were necessary during priming to this MHC class I(lo), II+ tumor, these data indicate that major histocompatibility complex (MHC) class I+, II+ antigen- presenting cells (APCs) were required for the T-cell antitumor response. Coexpression of GM-CSF and IFN-γ, both of which have immunostimulatory activities on antigen-presenting cells, abrogated the tumorigenic potential of this tumor and increased immunogenicity over N-2a/IFN but not N-2a/GM. Vaccination of mice with preexisting retroperitoneal tumors with irradiated N-2a/GM and irradiated N-2a/IFN/GM improved survival. There was a trend for nonirradiated transduced cells to be more immunogenic than their irradiated counterparts. Immunohistochemistry of tissues from the vaccination site revealed a pronounced macrophage infiltration associated with nonirradiated N-2a/GM and N-2a/IFN/GM. These data suggest that vaccination involving nonirradiated neuroblastoma cells transduced with genes that stimulate APCs may be a useful approach in stimulating antitumor T-cell responses.

Original languageEnglish (US)
Pages (from-to)113-124
Number of pages12
JournalJournal of Immunotherapy
Volume19
Issue number2
StatePublished - 1996
Externally publishedYes

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Neuroblastoma
Interferons
Immunization
Antigen-Presenting Cells
Neoplasms
Vaccination
Major Histocompatibility Complex
T-Lymphocytes
Histocompatibility Antigens Class I
Histocompatibility Antigens Class II
Sarcoma
Immunity
Immunohistochemistry
Macrophages
Genes

Keywords

  • GM-CSF
  • IFN-γ
  • Immunization
  • Mice
  • Neuroblastoma

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-γ. / Bausero, Maria A.; Panoskaltsis-Mortari, Angela; Blazar, Bruce R.; Katsanis, Emmanuel.

In: Journal of Immunotherapy, Vol. 19, No. 2, 1996, p. 113-124.

Research output: Contribution to journalArticle

Bausero, Maria A. ; Panoskaltsis-Mortari, Angela ; Blazar, Bruce R. ; Katsanis, Emmanuel. / Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-γ. In: Journal of Immunotherapy. 1996 ; Vol. 19, No. 2. pp. 113-124.
@article{498301388c854a94a255be55cd8db62b,
title = "Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-γ",
abstract = "Murine neuroblastoma, neuro-2a, was transduced with the retroviral vector MFG-granulocyte-macrophage colony-stimulating factor (GM-CSF), to examine immune stimulation conferred by localized GM-CSF production. Expression of murine GM-CSF by neuro-2a (N-2a/GM) significantly reduced its tumorigenicity. Moreover, immunization of mice with irradiated N-2a/GM cells resulted in a significant protective effect against live tumor challenge 14 days later. Approximately 41{\%} of mice immunized with irradiated N-2a/GM versus 0{\%} of those vaccinated with irradiated parental tumor survived. Surviving mice were rechallenged after 50 days with wild-type neuro-2a or with the Sa1 syngeneic sarcoma to discern whether the generated immunity was durable and tumor specific. All mice survived wild-type neuro-2a challenge, whereas none survived inoculation with Sa1. Because both CD4+ and CD8+ T cells were necessary during priming to this MHC class I(lo), II+ tumor, these data indicate that major histocompatibility complex (MHC) class I+, II+ antigen- presenting cells (APCs) were required for the T-cell antitumor response. Coexpression of GM-CSF and IFN-γ, both of which have immunostimulatory activities on antigen-presenting cells, abrogated the tumorigenic potential of this tumor and increased immunogenicity over N-2a/IFN but not N-2a/GM. Vaccination of mice with preexisting retroperitoneal tumors with irradiated N-2a/GM and irradiated N-2a/IFN/GM improved survival. There was a trend for nonirradiated transduced cells to be more immunogenic than their irradiated counterparts. Immunohistochemistry of tissues from the vaccination site revealed a pronounced macrophage infiltration associated with nonirradiated N-2a/GM and N-2a/IFN/GM. These data suggest that vaccination involving nonirradiated neuroblastoma cells transduced with genes that stimulate APCs may be a useful approach in stimulating antitumor T-cell responses.",
keywords = "GM-CSF, IFN-γ, Immunization, Mice, Neuroblastoma",
author = "Bausero, {Maria A.} and Angela Panoskaltsis-Mortari and Blazar, {Bruce R.} and Emmanuel Katsanis",
year = "1996",
language = "English (US)",
volume = "19",
pages = "113--124",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-γ

AU - Bausero, Maria A.

AU - Panoskaltsis-Mortari, Angela

AU - Blazar, Bruce R.

AU - Katsanis, Emmanuel

PY - 1996

Y1 - 1996

N2 - Murine neuroblastoma, neuro-2a, was transduced with the retroviral vector MFG-granulocyte-macrophage colony-stimulating factor (GM-CSF), to examine immune stimulation conferred by localized GM-CSF production. Expression of murine GM-CSF by neuro-2a (N-2a/GM) significantly reduced its tumorigenicity. Moreover, immunization of mice with irradiated N-2a/GM cells resulted in a significant protective effect against live tumor challenge 14 days later. Approximately 41% of mice immunized with irradiated N-2a/GM versus 0% of those vaccinated with irradiated parental tumor survived. Surviving mice were rechallenged after 50 days with wild-type neuro-2a or with the Sa1 syngeneic sarcoma to discern whether the generated immunity was durable and tumor specific. All mice survived wild-type neuro-2a challenge, whereas none survived inoculation with Sa1. Because both CD4+ and CD8+ T cells were necessary during priming to this MHC class I(lo), II+ tumor, these data indicate that major histocompatibility complex (MHC) class I+, II+ antigen- presenting cells (APCs) were required for the T-cell antitumor response. Coexpression of GM-CSF and IFN-γ, both of which have immunostimulatory activities on antigen-presenting cells, abrogated the tumorigenic potential of this tumor and increased immunogenicity over N-2a/IFN but not N-2a/GM. Vaccination of mice with preexisting retroperitoneal tumors with irradiated N-2a/GM and irradiated N-2a/IFN/GM improved survival. There was a trend for nonirradiated transduced cells to be more immunogenic than their irradiated counterparts. Immunohistochemistry of tissues from the vaccination site revealed a pronounced macrophage infiltration associated with nonirradiated N-2a/GM and N-2a/IFN/GM. These data suggest that vaccination involving nonirradiated neuroblastoma cells transduced with genes that stimulate APCs may be a useful approach in stimulating antitumor T-cell responses.

AB - Murine neuroblastoma, neuro-2a, was transduced with the retroviral vector MFG-granulocyte-macrophage colony-stimulating factor (GM-CSF), to examine immune stimulation conferred by localized GM-CSF production. Expression of murine GM-CSF by neuro-2a (N-2a/GM) significantly reduced its tumorigenicity. Moreover, immunization of mice with irradiated N-2a/GM cells resulted in a significant protective effect against live tumor challenge 14 days later. Approximately 41% of mice immunized with irradiated N-2a/GM versus 0% of those vaccinated with irradiated parental tumor survived. Surviving mice were rechallenged after 50 days with wild-type neuro-2a or with the Sa1 syngeneic sarcoma to discern whether the generated immunity was durable and tumor specific. All mice survived wild-type neuro-2a challenge, whereas none survived inoculation with Sa1. Because both CD4+ and CD8+ T cells were necessary during priming to this MHC class I(lo), II+ tumor, these data indicate that major histocompatibility complex (MHC) class I+, II+ antigen- presenting cells (APCs) were required for the T-cell antitumor response. Coexpression of GM-CSF and IFN-γ, both of which have immunostimulatory activities on antigen-presenting cells, abrogated the tumorigenic potential of this tumor and increased immunogenicity over N-2a/IFN but not N-2a/GM. Vaccination of mice with preexisting retroperitoneal tumors with irradiated N-2a/GM and irradiated N-2a/IFN/GM improved survival. There was a trend for nonirradiated transduced cells to be more immunogenic than their irradiated counterparts. Immunohistochemistry of tissues from the vaccination site revealed a pronounced macrophage infiltration associated with nonirradiated N-2a/GM and N-2a/IFN/GM. These data suggest that vaccination involving nonirradiated neuroblastoma cells transduced with genes that stimulate APCs may be a useful approach in stimulating antitumor T-cell responses.

KW - GM-CSF

KW - IFN-γ

KW - Immunization

KW - Mice

KW - Neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=0029874990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029874990&partnerID=8YFLogxK

M3 - Article

C2 - 8732694

AN - SCOPUS:0029874990

VL - 19

SP - 113

EP - 124

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 2

ER -